Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Deutsche Bank Keeps 'Buy' on Chiron


Deutsche Bank reiterates buy on Chiron (CHIR).

Analyst Dennis Harp says the higher guidance beat his Street-high $0.37 estimate and $0.32 consensus. Harp believes strong earnings per share resulted from firm sales of Chiron's influenza vaccine, which peak in the third quarter, and blood tests for detecting HIV and hepatitis C. He notes a recent trend in the drug for cystic fibrosis is positive.

Harp expects the company to report strength in other product lines. He says he will adjust estimates upward upon the company's release of details of third quarter results on Oct. 23.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus